| Schedule of Segment Loss |
The following table sets forth the Company’s segment loss disclosure for the three and six months ended June 30, 2026 and 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
R&D – Compensation and benefits (excludes stock-based compensation) |
|
$ |
2,495 |
|
|
$ |
3,217 |
|
|
$ |
4,625 |
|
|
$ |
6,512 |
|
R&D – Clinical trial costs |
|
|
1,331 |
|
|
|
2,448 |
|
|
|
3,943 |
|
|
|
5,298 |
|
R&D – Outsourced services & Consulting |
|
|
2,200 |
|
|
|
3,132 |
|
|
|
4,409 |
|
|
|
5,514 |
|
R&D – Lab and pharmacology supplies |
|
|
67 |
|
|
|
256 |
|
|
|
210 |
|
|
|
546 |
|
R&D – Other costs (1) |
|
|
629 |
|
|
|
440 |
|
|
|
1,009 |
|
|
|
1,036 |
|
G&A – Compensation and benefits (excludes stock-based compensation) |
|
|
1,893 |
|
|
|
1,528 |
|
|
|
3,276 |
|
|
|
3,102 |
|
G&A – Professional service fees |
|
|
2,266 |
|
|
|
810 |
|
|
|
3,047 |
|
|
|
1,807 |
|
G&A – Insurance |
|
|
136 |
|
|
|
202 |
|
|
|
335 |
|
|
|
420 |
|
G&A – Other costs (2) |
|
|
542 |
|
|
|
618 |
|
|
|
1,003 |
|
|
|
1,344 |
|
Facilities related |
|
|
6,720 |
|
|
|
2,400 |
|
|
|
9,243 |
|
|
|
4,699 |
|
Stock-based compensation and depreciation |
|
|
4,480 |
|
|
|
2,010 |
|
|
|
6,134 |
|
|
|
4,124 |
|
Impairment of property and equipment |
|
|
1,625 |
|
|
|
— |
|
|
|
1,625 |
|
|
|
— |
|
Total operating expense |
|
|
24,384 |
|
|
|
17,061 |
|
|
|
38,859 |
|
|
|
34,402 |
|
Loss from operations |
|
|
(24,384 |
) |
|
|
(17,061 |
) |
|
|
(38,859 |
) |
|
|
(34,402 |
) |
Interest and other income, net |
|
|
691 |
|
|
|
1,386 |
|
|
|
1,611 |
|
|
|
2,969 |
|
Segment net loss |
|
$ |
(23,693 |
) |
|
$ |
(15,675 |
) |
|
$ |
(37,248 |
) |
|
$ |
(31,433 |
) |
(1)Includes expenses such as software licenses, database subscriptions, lab service contracts, travel, and other costs. (2)Includes expenses such as travel, investor relations services, software licenses, employee training and development, and other costs.
|